Fms样酪氨酸激酶3基因第二酪氨酸激酶结构域及WT1基因阳性的急性早幼粒细胞白血病1例

doi:10.16138/j.1673-6087.2021.02.014

内科理论与实践 ›› 2021, Vol. 16 ›› Issue (02): 131-133.doi: 10.16138/j.1673-6087.2021.02.014

Fms样酪氨酸激酶3基因第二酪氨酸激酶结构域及WT1基因阳性的急性早幼粒细胞白血病1例

孟莉, 吴涛(), 汉英, 薛锋, 毛东锋, 潘耀柱, 王存邦, 白海

中国人民解放军联勤保障部队第九四医院全军血液病中心,甘肃兰州 730050

收稿日期:2020-01-03 出版日期:2021-04-25 发布日期:2022-07-26
通讯作者: 吴涛 E-mail:wutaozhen@yeah.net
基金资助:
甘肃省科技计划项目(20JRSRA595)

Received:2020-01-03 Online:2021-04-25 Published:2022-07-26

摘要/Abstract

关键词: 急性早幼粒细胞白血病, Fms样酪氨酸激酶3基因第二酪氨酸激酶结构域, WT1基因, 维A酸, 亚砷酸

中图分类号:

R733.7

孟莉, 吴涛, 汉英, 薛锋, 毛东锋, 潘耀柱, 王存邦, 白海. Fms样酪氨酸激酶3基因第二酪氨酸激酶结构域及WT1基因阳性的急性早幼粒细胞白血病1例[J]. 内科理论与实践, 2021, 16(02): 131-133.

参考文献 15

[1]	Schiller GJ, Tuttle P, Desai P. Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(6): 982-990. doi: 10.1016/j.bbmt.2016.01.013 URL
[2]	Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis[J]. Leukemia, 2005, 19(8): 1345-1349. pmid: 15959528
[3]	Small D. FLT3 mutations: biology and treatment[J]. Hematology Am Soc Hematol Educ Program, 2006: 178-184.
[4]	Port M, Böttcher M, Thol F, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis[J]. Ann Hematol, 2014, 93(8): 1279-1286. doi: 10.1007/s00277-014-2072-6 pmid: 24801015
[5]	Chang P, Kang M, Xiao A, et al. FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia[J]. BMC Cancer, 2010, 10: 513-519. doi: 10.1186/1471-2407-10-513 URL
[6]	Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications[J]. Blood, 2008, 111(3): 1552-1559. doi: 10.1182/blood-2007-08-107946 pmid: 17940205
[7]	Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients[J]. Blood, 2008, 111(5): 2527-2537. doi: 10.1182/blood-2007-05-091215 URL
[8]	Gallogly MM, Lazarus HM, Cooper BW. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis[J]. Ther Adv Hematol, 2017, 8(9): 245-261. doi: 10.1177/2040620717721459 pmid: 29051803
[9]	Rossi G, Minervini MM, Carella AM, et al. Wilms’tumor gene(WT1) expression and minimal residual disease in acute myeloid leukemia//van den Heuvel-Eibrink MM. Wilms tumor[M]. Brisbane(AU): Codon Publications, 2016: 273-280.
[10]	Gray JX, McMillen L, Mollee P, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation[J]. Leuk Res, 2012, 36(4): 453-458. doi: 10.1016/j.leukres.2011.09.005 URL
[11]	Polák J, Hájková H, Maalaufová-Soukupová J, et al. Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression[J]. Exp Ther Med, 2012, 3(1): 129-133 doi: 10.3892/etm.2011.363 URL
[12]	Lyu X, Xin Y, Mi R, et al. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia[J]. PLoS One, 2014, 9(3): e92470. doi: 10.1371/journal.pone.0092470 URL
[13]	Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia[J]. J Clin Oncol, 2009, 27(31): 5195-5201. doi: 10.1200/JCO.2009.22.4865 URL
[14]	Roskoski R Jr. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies[J]. Pharmacol Res, 2016, 113(85): 395-408. doi: 10.1016/j.phrs.2016.09.011 URL
[15]	Zidan MA, Kamal Shaaban HM, Elghannam DM. et al. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype[J]. Hematology, 2014, 19(5):267-274. doi: 10.1179/1607845413Y.0000000129 URL

Fms样酪氨酸激酶3基因第二酪氨酸激酶结构域及WT1基因阳性的急性早幼粒细胞白血病1例

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 15

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张苏江，陈赛娟. 精准治疗有希望治愈肿瘤吗？[J]. 上海交通大学学报, 2021, 55(Sup.1): 55-57.
[2]	郭娟娟, 吴涛, 贾占武, 马利, 白海, 王存邦. WT1阳性急性髓细胞性白血病合并唐氏综合征一例报告[J]. 诊断学理论与实践, 2020, 19(05): 531-533.
[3]	李佳明, 张苏江, 严泽莹, 王莹, 刘之茵, 孙海敏, 陈玉宝, 陈钰,. 单药地西他滨比较沙利度胺联合全反式维A酸治疗1型骨髓增生异常综合征[J]. 内科理论与实践, 2018, 13(02): 98-102.
[4]	崔雯, 聂瑞敏, 王瑾, 奚晓东, 糜坚青,. 血红蛋白在三氧化二砷抑制血小板聚集中的功能研究[J]. 内科理论与实践, 2017, 12(02): 135-139.
[5]	师蕾, 翁香琴, 盛燕, 吴婧, 蔡循,. 全反式维A酸诱导U937细胞分化的研究[J]. 诊断学理论与实践, 2016, 15(01): 37-40.
[6]	强琬婷, 诸江,. 急性早幼粒细胞白血病小鼠模型中白血病细胞对骨髓基质细胞增殖及功能影响的研究[J]. 诊断学理论与实践, 2016, 15(01): 25-29.
[7]	李军民, 祝洪明,. 急性早幼粒细胞白血病的治疗进展和目前存在问题[J]. 内科理论与实践, 2015, 10(01): 1-7.
[8]	盖东征, 翁香琴, 盛燕, 吴婧, 蔡循,. MEK-ERK信号通路在全反式维A酸诱导急性早幼粒细胞白血病细胞分化中的作用研究[J]. 诊断学理论与实践, 2015, 14(01): 36-40.
[9]	赵潇然, 陈岩, 朱劲舟, 杨克, 陈秋静, 朱政斌, 金清清, 张凤如,. 全反式维A酸抑制细胞内凋亡信号和改善心肌缺血再灌注损伤的研究[J]. 内科理论与实践, 2014, 9(03): 189-192.
[10]	聂瑞敏, 崔雯, 王学锋, 奚晓东, 糜坚青, 王瑾,. 三氧化二砷抑制血小板聚集功能的研究[J]. 内科理论与实践, 2014, 9(03): 184-188.
[11]	戴健敏, 刘祥箴, 张武, 诸江,. 全反式维A酸诱导的部分分化的白血病细胞具有去分化能力[J]. 诊断学理论与实践, 2014, 13(02): 152-158.
[12]	盖东征, 盛燕, 蔡循,. Staurosporine诱导维A酸耐药早幼粒细胞白血病细胞株分化的研究[J]. 诊断学理论与实践, 2013, 12(06): 614-617.
[13]	沈志祥, 王黎,. 急性早幼粒细胞白血病治疗进展及存在的问题[J]. 内科理论与实践, 2013, 8(03): 167-170.
[14]	黄檬檬, 诸江, 胡炯,. 急性早幼粒细胞白血病小鼠模型中造血增殖、定位和迁移特点的研究[J]. 诊断学理论与实践, 2013, 12(03): 326-329.
[15]	丁晶, 丁飞, 张武, 李军民, 诸江,. c-Kit在急性早幼粒细胞白血病起始细胞中的作用[J]. 内科理论与实践, 2012, 7(03): 210-213.